Michael S. Leapman, MD, MHS | Source | Clinical Program Leader, Prostate & Urologic Cancers Program at Yale Cancer C...
Michael S. Leapman, MD, MHS
Michael was drawn to the field of urology for the opportunity to care for patients with urologic cancers. He aims, above all, to deliver the highest level of care possible with the utmost consideration and compassion for the impact that cancer places on patients, as well as their families, friends and communities.
-
Yale Cancer Center
Clinical Program Leader, Prostate & Urologic Cancers Program
-
Exploring Regional Variation in Genomic Testing and Imaging in Prostate Cancer - Michael S. Leapman
In an interview with Matthew Cooperberg, Michael Leapman discusses his research on the use of genomic tests and imaging in prostate cancer and the resulting national practice patterns. Leapman found significant regional variation in the utilization of these tests, with areas rich in urologists and prostate cancer care showing higher adoption rates. He also observed a correlation between...
Article
-
It's true. Yeah. Absolutely. Right. Genomics is abstract and patients often are confused about what genomic testing is. No matter how much we explain it to them and still... The most common misconception is that this is a genetic test that it measures some germline or an inherited risk that is deterministic of their outcome. There seems to be... These are effective and looking at the MRI can be helpful, but I think it has to be customized to the patient. There's some people where looking at an MRI image makes absolutely no sense and it can be distressing.
